Clinical profile and outcome of refractory convulsive status epilepticus in older children from a developing country

Lokesh Lingappa1, Ramesh Konanki1, Ravi Patel1

  • 1Department of Neurology, Rainbow Hospital for Women and Children, Hyderabad, India.

Seizure
|February 19, 2016
PubMed

Insights

Acute symptomatic etiology, often CNS infections, is a common cause of convulsive status epilepticus (CSE) in children. Refractory status epilepticus (RSE) significantly increases the risk of disability and mortality.

Area of Science:

  • Pediatric Neurology
  • Critical Care Medicine
  • Infectious Diseases

Background:

  • Convulsive status epilepticus (CSE) is a neurological emergency with significant morbidity and mortality in children.
  • Refractory status epilepticus (RSE) presents a therapeutic challenge, often requiring advanced management strategies.
  • Understanding the specific etiologies and outcomes of RSE in pediatric populations is crucial for improving patient care.

Purpose of the Study:

  • To investigate the causes, clinical progression, and outcomes of refractory convulsive status epilepticus (RSE) in children aged 2 to 12 years.
  • To identify risk factors associated with the progression from CSE to RSE.
  • To determine the impact of RSE on mortality and long-term disability.

Main Methods:

  • Retrospective analysis of 73 children diagnosed with CSE, aged 2-12 years.
  • Calculation of odds ratios to assess the relationship between variables and clinical course/outcome.
  • Survival analysis to evaluate mortality rates within the study cohort.

Main Results:

  • 45.2% of children with CSE progressed to RSE.
  • Acute symptomatic etiology, particularly CNS infections, was the most frequent cause (60.3%) and a predictor of RSE (OR 2.62).
  • RSE significantly increased the risk of severe sepsis (OR 6.08), acidosis (OR 14.77), mortality (21.2% in RSE vs. 7.5% in non-RSE), and 1-year disability (OR 7.08).

Conclusions:

  • Acute symptomatic etiology is a primary driver of CSE and progression to RSE in older children, especially in developing countries.
  • RSE is strongly linked to adverse outcomes, including increased mortality and significant disability at one year post-discharge.
  • Early identification and management of CSE, particularly in cases with acute symptomatic etiology, are critical to mitigate the risks associated with RSE.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.1K
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.0K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
327
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
937
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
369